| Mrs Sarah Michelle Wredling, FNP | |
|
4066 Summer Ave, Memphis, TN 38122-5225 | |
| (901) 452-7391 | |
| Not Available |
| Full Name | Mrs Sarah Michelle Wredling |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 4066 Summer Ave, Memphis, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003290826 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 20129 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Memorial Hospital | Memphis, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Francis Physician Network, Llc | 2365701943 | 66 |
News Archive
Targets to eliminate tuberculosis (TB) by 2050 are more likely to be met if new vaccines are developed for adults and adolescents instead of for infants, according to new research published in the journal Proceedings of the National Academy of Sciences.
Geroscience researchers studying the biology of aging briefly treated middle-aged mice with the drug rapamycin to gauge the long-term effects of short-term therapy on health and longevity.
Hubrecht Organoid Technology (HUB), and the health insurance companies CZ, Zilveren Kruis, and Menzis announced today that they will start a €3 million validation trial for use of HUB Organoid Technology to test if it can be used to determine the response of Cystic Fibrosis (CF) patients to new drug therapies.
Meanwhile, news outlets report on a range of other implementation issues, including the decision of Ohio Gov. John Kasich to follow through on forming a state-based exchange despite his opposition to the overhaul, changes to FSAs and the measure's impact on farmers.
› Verified 7 days ago
| Entity Name | Saint Francis Physician Network, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295258002 PECOS PAC ID: 2365701943 Enrollment ID: O20180129001351 |
News Archive
Targets to eliminate tuberculosis (TB) by 2050 are more likely to be met if new vaccines are developed for adults and adolescents instead of for infants, according to new research published in the journal Proceedings of the National Academy of Sciences.
Geroscience researchers studying the biology of aging briefly treated middle-aged mice with the drug rapamycin to gauge the long-term effects of short-term therapy on health and longevity.
Hubrecht Organoid Technology (HUB), and the health insurance companies CZ, Zilveren Kruis, and Menzis announced today that they will start a €3 million validation trial for use of HUB Organoid Technology to test if it can be used to determine the response of Cystic Fibrosis (CF) patients to new drug therapies.
Meanwhile, news outlets report on a range of other implementation issues, including the decision of Ohio Gov. John Kasich to follow through on forming a state-based exchange despite his opposition to the overhaul, changes to FSAs and the measure's impact on farmers.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Sarah Michelle Wredling, FNP 4066 Summer Ave, Memphis, TN 38122-5225 Ph: (901) 452-7391 | Mrs Sarah Michelle Wredling, FNP 4066 Summer Ave, Memphis, TN 38122-5225 Ph: (901) 452-7391 |
News Archive
Targets to eliminate tuberculosis (TB) by 2050 are more likely to be met if new vaccines are developed for adults and adolescents instead of for infants, according to new research published in the journal Proceedings of the National Academy of Sciences.
Geroscience researchers studying the biology of aging briefly treated middle-aged mice with the drug rapamycin to gauge the long-term effects of short-term therapy on health and longevity.
Hubrecht Organoid Technology (HUB), and the health insurance companies CZ, Zilveren Kruis, and Menzis announced today that they will start a €3 million validation trial for use of HUB Organoid Technology to test if it can be used to determine the response of Cystic Fibrosis (CF) patients to new drug therapies.
Meanwhile, news outlets report on a range of other implementation issues, including the decision of Ohio Gov. John Kasich to follow through on forming a state-based exchange despite his opposition to the overhaul, changes to FSAs and the measure's impact on farmers.
› Verified 7 days ago
Michelle L Rush, MSN, APRN, BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 880 Madison Ave, Memphis, TN 38103 Phone: 901-545-6969 Fax: 901-545-1711 | |
Mrs. Leslie Rhodes, PNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 51 N Dunlap St Ste 100, Memphis, TN 38105 Phone: 901-287-7337 Fax: 901-937-6681 | |
Gwendolyn Watson, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 201 Poplar Ave, Memphis, TN 38103 Phone: 901-545-2445 | |
Barbara A Overbey, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 825 Ridge Lake Blvd, Memphis, TN 38120 Phone: 901-685-2200 Fax: 901-259-2715 | |
Florida Allen, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3362 S 3rd St, Memphis, TN 38109 Phone: 901-701-2510 Fax: 901-260-8598 | |
Teri Williams, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3530 Hickory Hill Rd, Memphis, TN 38115 Phone: 901-881-6686 |